Non small cell lung cancer;Epidemiologie, facteurs pronostiques, bilan d'extension et traitement des cancers bronchiques non a petites cellules

Bulletin du Cancer

Volumn 86, Issue SUPPL. 3, 1999, Pages 17-41

  André, Fabrice ^a   Jacot, William ^a   Pujol, Jean Louis ^b   Grunenwald, Dominique ^c   Le Chevalier, Thierry ^d  

^a Assoc d'Enseignement Rech I   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c INSTITUT MUTUALISTE MONTSOURIS   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Diagnosis; Epidemiology; Non small cell lung cancer; Prognosis; Radiotherapy; Surgery

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL; TELOMERASE; TENIPOSIDE; TIRAPAZAMINE; UFT; VINDESINE;

CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; GENE THERAPY; HUMAN; LUNG CARCINOGENESIS; LUNG LOBECTOMY; LUNG NON SMALL CELL CANCER; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; ONCOGENE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; REVIEW; RISK FACTOR; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; LUNG TUMOR; PATHOLOGY; POLLUTION; SMOKING;

CARCINOMA, NON-SMALL-CELL LUNG; ENVIRONMENTAL POLLUTION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; RISK FACTORS; SMOKING;

EID: 0032700493     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (181)

1. World Health Organization. The World Health Organization histological typing of the lung tumors. 2nd Ed. Am J Clin Pathol 1982; 77: 123.
2. Yesner R, Carter D, Pathology of carcinoma of the lung. Changing patterns. Clin Chest Med 1982; 3: 257-89.
3. Hansen HH, Kristjansen PEG. Chemotherapy of small cell lung cancer. Eur J Cancer 1991; 27: 342-9.
4. Schottenfeld O. Epidemiology of lung cancer. In: Pass HI, ed. Lung cancer: principles and practices. Philadelphia: Lippincott-Raven, 1996; 305-21.
5. Fry WA, Menck HR, Winchester DP. The National Cancer Data Base Report on Lung Cancer. Cancer 1996; 77: 1947-55.
6. Garshick E, Schenker MB, Munoz A, et al. A retrospective cohort study of lung cancer and diesel exaust exposure in railroad workers. Am Rev Respir Dis 1988; 137: 820.
7. Rezvani A, Doyon F. Tendances récentes de la mortalité par cancer bronchique en France. Bull Cancer 1996; 83: 910-4.
8. Parkin DM, Läära E, Muir CR. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988; 41: 184-97.
9. Zheng T, Holford TR, Boyle P, et al. Time trend and age-period-cohort effect on the incidence of histologic types of lung cancer in Connecticut, 1960-1989. Cancer 1994; 74: 1556-67.
10. Travis WD, Lubin J, Ries L, Devesa S. United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females. Cancer 1996; 77: 2464-70.
11. Olsen JH. Epidemiology of lung cancer. Eur Respir Mon 1995; 1: 1-17.
12. Thun MJ, Lally CA, Flannery JT, et al. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997; 89: 1580-6.
13. Hoffmann D, Rivenson A, Hecht SS. The biological significance of tobacco specific N-nitrosamines : smoking and adenocarcinoma of the lung. Crit Rev Tox 1996; 26: 199-211.
14. Doll R, Hill AB. A study of the etiology of carcinoma of the lung. Br Med J 1952; 2: 1271.
15. Abelin T, Gsell OR. Relative risk of pulmonary cancer in cigar and pipe smokers. Cancer 1967; 20: 1288.
16. Damber LA, Larsson LG. Smoking and lung cancer with special regard to type of smoking and type of cancer : a case-control study in north Sweden. Br J Cancer 1986; 53: 673.
17. Bofferta P, Perskagen G, Jockel KH, et al. Cigar and pipe smoking and lung cancer risk: a multicenter study from Europe. J Natl Cancer Inst 1999; 91: 697-701.
18. Schoenberg JB, Klotz JB, Wilcox HB, et al. Case-control study of residential radon and lung cancer among New Jersey women. Cancer Res 1990; 50: 6520.
19. Pershagen G, Akerblom G, Axelson O, et al. Residential radon exposure and lung cancer in Sweden. N Engl J Med 1994; 330: 159.
20. Létourneau EG, Krewski D, Choi NW, et al. Case-control study of residential radon and lung cancer in Winnipeg, Manibota, Canada. Am J Epidemiol 1994; 140: 310.
21. Blot WJ, Zu ZY, Boice JD, et al. Indoor radon and lung cancer in China. J Natl Cancer Inst 1990; 82: 1025.
22. Lubin JH, Boice JD. Lung cancer risk from resident radon: metaanalysis of eight epidemiologic studies. J Natl Cancer Inst 1997; 89: 49-57.
23. Wang SY, Hu YL, Wu YL, et al. A comparative study of the risk factors for lung cancer in Guangdong, China. Lung Cancer 1996; 14 (suppl. 1): 99-105.
24. Dai XD, Lin CY, Sun XW, et al. The etiology of lung cancer in nonsmoking females in Harbin, China. Lung Cancer 1996; 14 (suppl. 1): 85-91.
25. Nyberg F, Afrenius V, Svartengren K, et al. Dietetary factors and risks of lung cancer in never smokers. Inst Cancer 1998; 78: 430-6.
26. Schekelle RB, Tangney CC, Rossof AH, et al. Serum cholesterol, beta-carotene, and risk of lung cancer. Epidemiology 1992; 3: 282.
27. Goodman MT, Hankin JH, Wilkens LR, et al. High-fat foods and the risk of lung cancer. Epidemiology 1992; 3: 288.
28. Vyzula R, Remick SC. Lung cancer in patients with VTH-infection. Lung Cancer 1996; 15: 325-39.
29. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of Aids associated malignant disorders, Lancet 1998; 351: 1833-9.
30. Spitz MR, Bondy ML. Genetic susceptibility to cancer. Cancer 1993; 72: 991-5.
31. Duche JC, Barre J. Lack of relationship between the polymorphism of debrisoquin oxidation and lung cancer. Br J Pharmacol 1991; 31: 533-6.
32. Sugimura H, Caporaso NE, Modali RV, et al. Association of rare alleles of the Harvey ras protooncogene locus with lung cancer. Cancer Res 1990; 50: 1857-62.
33. Braun MM, Caporaso NE, Page WP, et al. Genetic component of lung cancer: cohort study of twins. Lancet 1994; 344: 440.
34. Mountain CF. Revision in the international system for staging lung cancer. Chest 1997; 111: 1710-7.
35. Vanstenkiiste JF, De Leyn PR, Deneffe GJ, et al. Clinical prognostic factors in surgically treated stage IIIA-N2 NSCLC : analysis of the litterature. Lung Cancer 1998; 19: 3-13.
36. Ruckdeschel JC. Combined modality therapy of non small cell lung cancer. Semin Oncol 1997; 24: 429-39.
37. Grunenwald D, Le Chevalier T. Stage IIIA category of NSCLC: a new proposal. J Natl Cancer Inst 1997; 89: 88-9.
38. Charloux A, Hedelin G, Dietemann A, et al. Prognostic value of histology in patients with non small tell lung cancer. Lung Cancer 1997; 17: 123-34.
39. Weiner DB, Norberg J, Robinson R, et al. Expression of the Neu gene encoded protein in human nonsmall cell carcinoma of the lung. Cancer Res 1990; 50: 421.
40. Carbone DP. Biology of lung cancer. Semin Oncol 1997; 24: 388-401.
41. Xu HJ, Hu SX, Cagle PT, Moore GE, Benedict WF. Absence retinoblastoma protein expression in primary NSCLC. Cancer Res 1991; 51: 2735.
42. Winter SF, Minna JD, Johnson BE, et. al. Development of antibodies against p53 in lung cancer patients appears to be independent on the type of p53 mutations. Cancer Res 1992; 52: 4168.
43. McCarty TM, Liu XP, Sun JY, Peralta EA, Diamond DJ, Ellenhorn JDI. Targeting p53 for adoptive T-cell immunotherapy. Cancer Res 1998; 58: 2601-5.
44. Frizzelle SP, Brunner T, Nichans GA, et al. Expression of Fas-ligand by human lung cancer. Prof Am Ass Cancer Res 1997; A1300.
45. Passlick B, Izbicki JR, Simmel S, et al. Expression of major histocompatibility class I and II antigens and intercellular adhesion molecule-1 on operable non-small cell lung carcinoma : frequency and prognostic significance. Eur Cancer 1994; 30: 376-81.
46. Hiyama K, Hiyama E, Ishioka S, et al. Telomerase activity in small cell and non small cell lung cancer. J Natl Cancer Inst 1995; 87: 895-902.
47. Denissenko MF, Pao A, Tang MS, Pfeifer GP. Preferential formation of benzopyrene aducts atlung cancer mutational hotspots in p53. Science 1996; 274: 430-2.
48. Wisiuba II, Lam S, Berhens C, et al. Molecular damage in the bronchial epithelium of current and former smokers. J Natl Cancer Inst 1997; 89: 1366-73.
49. Mao L, Lee JS, Kurie JM. Clonal genetics alterations in the lung of current and former smokers. J Natl Cancer Inst 1997; 89: 857-62.
50. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as prognostic indicator of survival in non small cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881-6.
51. Angeletti CA, Lucchi M, Fontanini C. Prognostic significance of tumoral angiogenesis in completely resected late stage lung carcinoma (IIIAN2). Cancer 1996; 78: 409-15.
52. Pantel K, Izbicki J, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non small cell lung cancer without overt metastases. Lancet 1996; 347: 649-53.
53. Ohgami A, Mitsudomi T, Suggio K, et al. Micrometastatic tumor cells in the bone marrow of patients with non small cell lung cancer. Ann Thorac Surg 1997; 64: 363-7.
54. Fontanini G, Vignati S, Bigini D, et al. Bcl2 protein : a prognostic factor inversely correlated to p53 in non small cell lung cancer. Br J Cancer 1995; 71: 1003-7.
55. Ritter JH, Dresler CM, Wick MR. Expression of Bcl-2 protein in stage T1N0M0 non small cell lung carcinoma. Hum Pathal 1995; 26: 1227-32.
56. Anton RC, Brown RW, Younes M, et al. Absence of prognostic significance of Bcl-2 immunopositivity in non-small cell lung cancer : analysis of 427 cases. Hum Pathol 1997; 28: 1079-82.
57. Pastorino U, Andreola S, Tagliabue E, et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J Clin Oncol 1997; 15: 2858-65.
58. Apolinaro R, Van Der Valk P, De Jong JS, et al. Prognostic value of the expression of p53, bcl-2 and bax oncoprotein and neovascularisation in patients with radically resected NSCLC. J Clin Oncol 1997; 15: 2456-66.
59. Vega FJ, Iniesta P, Caldes T, et al. p53 exon 5 mutations as a prognostic indicator of shortened survival in NSCLC. Br J Cancer 1997; 76: 44-51.
60. Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and p53 mutations are an independent unfavorable prognostic indicator in patients with NSCLC. Br J Cancer 1997; 75: 1125-30.
61. Fujino M, Dosaka H, Harada M, et al. Prognostic significance of p53 and K-ras expression in non small cell lung cancer. Cancer 1995; 76: 2457-63.
62. Dosaka H, Hu SX, Fujino M, et al. Altered retinoblastoma protein expression in non small cell lung Cancer: its synergistic effect with altered ras and p53 protein status on prognosis, Cancer 1997; 79: 1329-37.
63. Li S, Rosell R, Urban A, et al. K-ras gene point mutation: a stable tumor marker in non small cell lung carcinoma. Lung Cancer 1994; 11: 19-27.
64. Rosell R, Li S, Skacel Z, et al. Prognostic impact of mutated K-ras gene in surgically resected NSCLC patients. Oncogene 1993; 8: 2407-12.
65. Albanell J, Lonardo F, Rusth V, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation and advanced pathologic stage. J Natl Cancer Inst 1997; 89: 1609-15.
66. Yang CT, Lee MH, Lan RS, Chen JK. Telomerase activity in pleural effusion : diagnostic significance. J Clin Oncol 1998; 16: 567-72.
67. American thoracic Society/European Respiratory Society, Prettcatment evaluation of non small cell lung cancer. Am J Respir Crit Care Med 1997; 156: 320-32.
68. Yahata N, Ohyashiki JH, Iwana H, et al. Telomerase activity in lung cancer cells obtained from bronchial washings. J Natl Cancer Inst 1998; 90: 684-90.
69. Ahrendt SA, Chow JT, Xu LH, et al. Molecular detection of tumor cells in bronchoalvcolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 1999; 91: 332-9.
70. Tockman MS, Mulshine JL, Piantadosi S, et al. Prospective detection of preclinical lung cancer: results from two studies of heterogenous nuclear ribonucleoprotein A2/B1 overexprcssion. Clin Cancer Res 1997; 3: 2237-46.
71. Sone S, Takashima S, Li F, et al. Mass screening for lung with mobile spiral computed tomography scanner. Lancet 1998; 351: 1242-5.
72. Lam S, Mac Aulay C, Hung J, et al. Detection of dysplasia and carcinoma in situ with a lung imaging fluorescence endoscope device. J Thorac Cardiovasc Surg 1993; 105: 1035-40.
73. Lam S, Kennedy T, Unger M, et al. Localization of bronchial intraepithclial neoplastic lesions by fluorescence bronchoscopy. Chest 1998; 113: 696-702.
74. Webb W, Garsonis C, Zerhouni A, et al. CT and MR staging in non small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1992; 182: 319-23.
75. Silvestri G, Littenberg B, Colice GL. The clinical evaluation for detecting metastatic lung cancer: a metaanalysis. Am J Respir Crit Care Med 1995; 152: 225-30.
76. American Society of Clinical Oncology. Clinical practice guidelines for the trearment of unresectable non small cell lung cancer. J Clin Oncol 1997; 15: 2996-3018.
77. Milleron B, Guigay J, Rugeri L, et al. Le bilan d'extension des adénocarcinomes bronchiques doit-il différer de celui des autres cancers bronchiques non à petites cellules ? Pneumol Clin 1992; 48: 159-62.
78. Wiersema MJ, Hassig WM, Hawes RH, et al. Mediarinal lymph node detection with endosonography. Gastrointestinal Endoscopy 1993; 39: 788-93.
79. Lee N, Inoue K, Yamamoto R, et al. Patterns of internal echos in lymph nodes in htc diagnosis of the lung cancer metastasis. World J Surg 1992; 16: 986-94.
80. Gress FG, Savides TJ, Sandler A, et al. Endoscopic ultrasound endoscopically directed fine needle aspiration and computed tomography in the preoperative staging of non small cell lung cancer. Ann Intern Med 1997; 127: 604-12.
81. Valk PE, Pounds TR, Hopkins DM, et al. Staging non small cell lung cancer by whole body positron emission tomograpbic imaging. Ann Thorac Surg 1995; 60: 1573-81.
82. Bury T, Paulus P, Dowlati A, et at. Staging of the mediastinum: value of positron emission tomography imaging in non small cell lung cancer. Eur Resp J 1996; 9: 2560-1.
83. Steinert HC, Hauser M, Alleman F, et al. Non small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node-mapping and sampling. Radiology 1997; 202: 441-6.
84. Sazon DA, Santiago SM, Sou Hoo GW, et al. Fluorodeoxyglucose positron emission tomography in the detection and staging of lung cancer. Am J Resp Crit Care Med 1996; 153: 417-21.
85. Patz EF, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC. Persistent or recurrent bronchogenic carcinoma : detection with PET and 2F18deoxyglucose. Radiobiology 1993; 188: 487-90.
86. Inoue T, Kim EE, Komaki R, et al. Detecting recurrent or residual lung cancer with FDG-PET. J Nucl Med 1995; 36: 788-93.
87. Sociëré de pneumologie de langue française. Recommandations concernant l'utilisation des marqueurs tumoraux sériques dans la prise en charge des cancers bronchiques primitifs. Cancérologie Aujourd'hui 1997; 6: 293-307.
88. The ATBC Cancer Prevention Study Group, The effect of vitamine E and B carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330: 1029-35.
89. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of beta carotene and vitamine A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-5.
90. Hennekens C, Burring JF, Manson JE, et al. Lack of effect of long term supplementation with B carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med 1996; 334: 1145-9.
91. Blot WJ, Li JY, Taylor PR, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin, mineral combination, cancer incidence, and disease specific mortality in general population. J Natl Cancer Inst 1993; 85: 1483-92.
92. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of head and neck. N Engl J Med 1990; 323: 795-801.
93. Pastorino U, Infante M, Maioli M, et al. Adjuvant treatment of stage I lung cancer with highdose vitamine A. J Clin Oncol 1993; 11: 1216-22.
94. Xu XC, Sozzi G, Lee J, et al. Suppression of retinoic receptor B in non small cell lung cancer in vivo : implications for lung cancer development. J Natl Cancer Inst 1997; 89: 624-9.
95. Ginsberg RT, Rubinstein LV, Randomized trial of lobectomy versus limited resection for T1 N0 non small cell lung cancer. Ann Thorac Surg 1995; 60: 615-23.
96. Ichinose Y, Yano T, Yokoyama H, et al. The correlation between tumor size and lymphatic vessel invasion in resected peripheral stage I non small cell lung cancer. J Thorac Cardiovasc Surg 1994; 108: 684-6.
97. Izbicki JR, Thetter O, Habekost M, et al. Radical systemic mediastinal lymphadenectomy in non small tell lung cancer: a randomized controlled trial. Br J Surg 1994; 81: 229-35.
98. Asamura H, Nakyama H, Kondo H, et al. Lymph node involvement, recurrences and prognosis in resected small, peripheral, non small cell lung cancer: are these carcinoma candidates for video assisted lobectomy? J Thorac Surg 1996; 111: 1125-34.
99. Sutedja G, Koppenol W, Stam J, Nd-YAG laser under local anaesthesia in obstructive endobronchial tumours. Respiration 1991; 58: 238-40.
100. Cavalière S, Foccoli P, Farina PL. Nd : YAG laser bronchoscopy : a five-year experience with 1,396 applications in 1000 patients. Chest 1998; 94: 15-21.
101. Moghissi K, Dixon K, Stringer M, et al. The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer: experience of 100 cases. Eur J Cardiothorac Surg 1999; 15: 1-6.
102. Sutedja T, Baas P, Stewart F, et al. A pilot study of photodynamic therapy in patients with inoperable non-small cell lung cancer. Eur J Cancer 1992; 28: 1370-3.
103. Marthur PN, Wolf KM, Busk MF, et al. Fiberoptic bronchoscopic cryotherapy in the management of tracheobronchial obstruction. Chest 1990; 110: 718-23.
104. Walsh DA, Maiwand MO, Nath AR, et al. Bronchoscopic cryotherapy for advanced bronchial carcinoma. Thorax 1990; 45: 509-13.
105. Warram J. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial: a collaborative study. Cancer 1975; 36: 914-25.
106. Shields TW. Preoperative radiation therapy in the treatment of bronchial carcinoma. Cancer 1972; 5: 1388-93.
107. Arriagada R. Current strategies for radiation theapy in non small cell lung cancer. Chest 1997; 112: 209-13.
108. Stewart LA, Burdett S, Souhami RI. Post-operative radiotherapy in non small cell lung cancer: a metaanalysis using individual data from randomized trials. Proc Am Soc Clin Oncol 1998; A1760.
109. Gauden S, Ramsay J, Tripcony L. The curarive treatment by radiotherapy alone in stage I non small cell lung carcinoma of the lung. Chest 1995; 108: 1278-82.
110. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Hyperfractionated radiotherapy alone for clinical stage I non small cell lung cancer. Int J Rad Oncol Biol Phys 1997; 38: 521-5.
111. Slotman BJ, Njo KH, Karim AB. Urative radiotherapy for technically operable stage I non small cell lung cancer. Int J Radiat Oncol Biol Phys 1994; 29: 33-7.
112. Wurschmidt F, Buncmann H, Bunnemean C, Beck HP, Heilmann HP. Inoperable NSCLC: a retrospective analysis of 427 patients treated with high dose radiorherapy. Int J Radiat Oncol Biol Phys 1994; 28: 583-8.
113. Kagami Y, Nishion M, Narimatsu N, et al. Radiotherapy for locoregional recurrent tumors after resection of non small cell lung cancer. Lung Cancer 1998; 20: 31-5.
114. Tredaniel J, Hennequin C, Zacman G, et al. Prolonged survival after high dose rate endobronchial radiation for malignant airway obstruction. Chest 1994; 105: 767-72.
115. Saito M, Yokoyama A, Kurita Y, et al. Treatment of roentgenographically occult endobronchial carcinoma with external beam radiotherapy and intraluminal low dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1996; 58: 1447-51.
116. Perol M, Caliandro R, Pommier P, et al. Curative irradiation of limited endobronchial carcinomas with high dose rate brachytherapy. Results of a pilot study. Chest 1997; 111: 1417-23.
117. Brach B, Buhler C, Hayman MH, Joyner LR, Liprie SF. Percutaneous computed tomography-guided fine needle brachytherapy of pulmonary malignancies. Chest 1994; 106, 268-74.
118. Speiser B. Remote after loading brachytherapy for the local control of endobronchial carcinoma. Int J Radiat Oncol Biol Phys 1993; 25: 579-87.
119. Huber RM, Fisher R, Hautmann H, Pollinger B, Haussinger K, Wendt T. Does addditional brachytherapy improve the effect of external irradiation? A prospecrive, randomized study in central lung tumors. Int J Radiat Oncol Biol Phys 1997; 38: 533-40.
120. Robertson JM, Ten Haken RK, Hazuka MB, et al. Dose escalation fot non small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys 1997; 37: 1079-85.
121. Sibley GS, Mundt AJ, Shapiro C, et al. The treatment of stage III non small cell lung cancer using high dose conformal radiotherapy. Int J Radiat Oncol Biol Phys 1995; 33: 1001-7.
122. Sause WT, Scott C, Taylor J, et al. RTOG 88-08 and ECOG 4588: preliminary results of a phase III trial in advanced unresecrable non small cell lung cancer. J Natl Cancer Inst 1995; 87: 198.
123. Strushke M, Thames HD. Hyperfractionated radiotherapy of human tumors: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 1997; 37: 259-67.
124. Saunders M, Dische S, Barret A, et al. Continuous hyperfractionated accelerated (Chart) versus conventional radiotherapy in non small cell lung cancer: a randomised multicentic trial. Lancet 1997; 350: 161-5.
125. Shaake-Koning C, Van den Bogaerr W, Dalesio O, et al. N Engl J Med 1992; 326: 524-30.
126. Non Small Cell Lung Cancer Collaborative Group. Chemotherapy in NSCLC: a metaanalysis using updated data on individual patients from 52 randomized trial. Br J Med 1995; 311: 899-909.
127. Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced NSCLC: results of European multicenter trial including 612 patienrs. J Clin Oncol 1994; 12: 360-7.
128. Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial of cisplatine versus cisplatine plus navelbine in treatment of advanced non small celll lung cancer, report of SWOG 9308. Proc Am Soc Clin Oncol 1996; A1110.
129. Wosniak AJ, Kawahara M, Furuse K, Nishiwaki Y, et al. Randomized study of vinorelbine or vindesinc with cisplatin and mitomycin as induction chemotherapy in stage IIIB and IV non small lung cancer. Proc Am Soc Clin Oncol 1998; A1796.
130. Perrone F, Rossi A, Iannello GP, et al. Vinorelbine plus best supportive care versus best supportive care in the treatment of advanced NSCLC elderly patients: results of a phase III study. Proc Am Soc Clin Oncol 1998; A1752.
131. Bonomi PD, Kim K, Chang A, et al. Phase III trial comparing VP16/cisplatin versus paclitaxel/cisplatin + G-CSF versus cisplatin: ECOG, 1996. Proc Am Soc Clin Oncol 1996; A1145.
132. Giaccone G, Postmus P, Debruyne ??, et al. Final results of an EORTC phase III study of paclitaxel versus teniposide in combination with cisplatine in advanced NSCLC. Proc Am Soc Clin Oncol 1997; A1653.
133. Garzemeier U, Von Pawel J, Gottfried M, et al. Phase III comparative study of high dose cisplatin versus a combination of paclitaxel and cisplatin in patients with advanced NSCLC. Proc Am Soc Clin Oncol 1997; A1748.
134. Belani CP, Natale RB, Lee JS, et al. Randomized phase III trial comparing cisplatin/eroposid versus carboplarin/paclitaxel in advanced and metastatic non small cell lung cancer. Proc Am Soc Clin Oncol 1998; A1751.
135. Fossella FV, Lee JS, Shin DM, et al. Phase II study of docetaxel for advanced or metastatic platinum refractory non small cell lung cancer. J Clin Oncol 1995; 13: 645-51.
136. Sandler A, Nemunaitis J, Dehnam C, et al. Phase III study of cisplatin with or without gemcitabine in patients with advanced NSCLC. Proc Am Soc Clin Oncol 1998; A1747.
137. Crino L, Conte P, De Marinis F, et al. A randomized trial of gemcitabine cisplatin (Gp) versus mitomycin, ifosfamid and cisplatin in advanced non small cell lung cancer. Proc Am Soc Clin Oncol 1998; A1750.
138. Cardenal H, Rosell R, Anton A, et al. Gemcitabine + platine in advanced NSCLC patients: preliminary randomized phase III results. Proc Am Soc Clin Oncol 1997; 1648.
139. Fukuoka M, Niitani H, Suzaki A, et al. A phase II study of CPTI1, a new derivative of camptothecin for previously untreated non small cell lung cancer. J Clin Ocol 1992; 10: 16-20.
140. Nakagawa K, Fukuoka M, Niitani H. Phase II study of irinotecan and cisplatin in patients with advanced non small cell lung cancer. Proc Am Soc Clin Oncol 1993; A1104.
141. Von Pawel R, Von Roemeling J. Survival benefit from tirazone and cisplatin in advanced NSCLC patients: final results from the international phase III catapult I trial. Proc Am Soc Clin Oncol 1998; A1749.
142. Lorusso V, Mancarella S, Carpagnano F, et al. Gemcitabine plus vinorelbine in patients with stage IIIB-IV non small cell lung cancer: a phase II study. Prof Am Soc Clin Oncol 1998; A1808.
143. Georgoulias V, Kouroussis C, Androulakis N, et al. Front line treatment of advanced non small cell lung cancer with docetaxel and gemcitabine: a multicenter phase II trial. Proc Am Soc Clin Oncol 1998; A1819.
144. Feld R. Chemotherapy as adjuvant therapy for completly resected NSCLC: have we made progress ? J Clin Oncol 1996; 14: 1045-7.
145. Depierre A, Milleron B, Moro D, et al. Phase III trial of neoadjuvant chemotherapy in resectable stage I, II, IIA non small cell lung cancer: the French experience. Proc Am Soc Clin Oncol 1999; A1792.
146. Rosenthal DI, Okani O, Corak J, et al. Seven weekcontinuous infusion paclitaxel plus concurrent radiation therapy for locally advanced non-small cell lung cancer: a phase I study. Semin Oncol 1997; 24 (suppl. 12): 96-100.
147. Socinski MA, Clark JA, Halle J, et al. Induction therapy with carboplatine paclitaxel followed by concurrent carboplatine paclitaxel and dose escalating conformal radiotherapy in the treatment of locally advanced, unresectable non small cell lung cancer: preliminary report of a phase I trial. Semin Oncol 1997; 24 (suppl. 12): 117-22.
148. Comella G, Frasci G, Scoppa G, et al. Weekly pacliraxel cisplatin with concurrent radiotherapy in patients with locally advanced non small cell lung cancer: a phase I study. Semin Oncol 1997; 24 (suppl. 12): 113-6.
149. Langer CJ, Movsas B, Hudes R, et al. Induction pacliraxel carboplatine followed by concurrent chemoradiotherapy in patients with unrecetable, locally advanced NSCLC. Semin Oncol 1997; 24 (suppl. 12): 89-95.
150. Vokes EE, Haraf DJ, Master G. Vinorelbine cisplatin and concomitant radiation therapy for advanced malignancies of the chest: a phase I study. Semin Oncol 1996; 23: 48-52.
151. Saka H, Shimokata K, Yoshida S, et al. Irinotccan and concurrent radiotherapy in locally advanced NSCLC: a phase II study of Japan Clinical Oncology Group. Proc Am Soc Clin Oncol 1998; A1607.
152. Gregor A. Gemcitabine plus radiotherapy for non small cell lung cancer. Semin Oncol 1997; 24 (suppl. 8): 39-41.
153. Vokes EE, Leopold KA, Herndon JE, et al. A CALGB randomized trial of gemcitabine or paclitaxel or vinorelbine with cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage IIIB NSCLC: feasibility data. Proc Am Soc Clin Onrol 1997: A1636.
154. Tursz T, Le Cesne A, Baldeyrou P. Phase I study of a recombinant adenovirus mediated gene transfer in lung cancer patients. J Natl Cancer Inst 1996; 88: 1857-63.
155. Tursz T, Le Cesne A, Farace F, et al. Intratumor gene transfer with recombinant adenoviral vector in lung cancer patients: an update of the French phase I study. Proc Am Ass Cancer Res 1997; A2295.
156. Roth JA, Nguyen D, Lawrence DD, et al. Retrovirus mediated wild type p53 gene transfer to tumor of patients with lung cancer. Nature Medecine 1996; 2: 986-91.
157. Swisher SG, Roth JA, Neumanitis J, et al. Adenoviral mediated p53 gene transfer in patients with advanced NSCLC. Proc Am Soc Clin Oncol 1998; A1659.
158. Timmons T, Burt K, Chema D, et al. Biodistribution of adenovirus-p53 in a phase I/II trial of gene therapy for NSCLC. Proc. Am Soc Clin Oncol 1998; A1660.
159. Praja SW, Torri J, Johnson M, et al. Phase I study of marimastar, a novel MMP inhibitor, administred orally to patients with advanced lung cancer. J Clin Oncol 1998; 16: 2150-7.
160. Nelson NJ. Inhibitors angiogenesis enter in phase III testing. J Natl Cancer Inst 1998; 90: 960-3.
161. Shennib HA, Landreneau R, Mulder DS, Mack M. Video-assisted thoracoscopic wedge resection of TI lung cancer in high risk patients. Ann Surg 1993; 218: 555-8.
162. André F, Grunenwald D, Pignon JP, et al. Survival of resected N2 NSCLC: heterogeneity of prognosis and evidence for a subclassification. Proc Am Soc Clin Oncol 1999; A1802.
163. Rosell R, Lopez Cabrerizo MP, Astudillo J, et al. Preoperative chemotherapy for stage IIIA NSCLC. Curr Op Oncol 1996; 9: 149-55.
164. Sugarbaker DJ, Herndon J, Decamp MM, et al. N2 status at resection predict long term outcome following induction therapy for stage IIIA NSCLC: CALGB8935. Proc Am Soc Clin Oncol 1998; A1739.
165. Rosell R, Gomez J, Camps C. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non small cell lung cancer. N Engl J Med 1994; 330: 153-8.
166. Roth JA, Fossella F, Komaki R. A randomized trial comparing peri-operarive chemotherapy and surgery with surgery alone in resectable stage IIIA non small cell lung cancer. J Natl Cancer Inst 1995; 109: 473-83.
167. Sawyer TE, Bonner JA, Gould PM, et al. The impact of surgical adjuvant thoracic radiation therapy for patients with non small cell lung cancer with ipsilateral mediastinal lymph node. Cancer 1997; 80: 1399-408.
168. Fleck J, Camargo J, Godoy D, et al. Chemoradiation therapy alone versus chemotherapy alone is a neoadjuvant treatment for stage HINSCLC. Preliminary results of a phase III, randomized trial. Proc Am Soc Clin Oncol 1993; A1108.
169. Choi NC. Management of stage III NSCLC: progress in preoperative chemotherapy. Educational book. ASCO 1998; 276-93.
170. Albain KS, Rush VW, Crowley JJ, et al. Concurrent cisplatin-etoposide plus chest radiotherapy followed by surgery for stage IIIAN2 and IIIB non small cell lung cancer: mature results of SWOG phase study 8805. J Clin Oncol 1995; 13: 1880-92.
171. Eberhardt W, Wilke H, Stamatis C, et al. Preoperarive chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced NSCLC: mature results of a phase II trial. J Clin Oncol 1998; 16: 622-34.
172. Choi NC, Carcy RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice daily radiation and concurrent chemotherapy in stage HIA NSCLC. J Clin Oncol 1997; 15: 712-22.
173. Ruckedeschel JC. Combined modality therapy of non small cell lung cancer. Semin Oncol 1997; 24: 429-39.
174. Arriagada R, Le Chevalier T, Rekacewicz C, et al. Cisplatin-based chemotherapy in patients with locally advanced non small cell lung cancer: late analysis of a French randomized trial. Proc Am Soc Clin Oncol 1997; A1601.
175. Perez CA, Pajak TF, Rubin P, et al. Long term observation of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer 1987; 59: 1874-81.
176. Furuse K, Fukuoka M, Takada Y, et al. A randomized phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non small cell lung cancer: preliminary analysis. Proc Am Soc Clin Oncol 1997; A1649.
177. Bretel JJ, Arriagada R, Le Chevalier T, et al. Optimization of combined radiotherapy and chemotherapy in treatment of non small cell lung cancer. Cancer Radiother 1997; 1: 148-53.
178. Albain KS, Crowley JJ, Turrisi III, et al. Concurrent cisplatin/etoposide plus radiotherapy for pathologic stage IIIB non small cell lung cancer: a SWOG phase II study. Proc Am Soc Clin Oncol 1997; A1600.
179. Namikawa S, Mizuno T. Surgical treatment of T4 primary lung cancer. Jap J Thorac Surg 1997; 50: 90-4.
180. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases of the brain. N Engl J Med 1990; 322: 494-500.
181. Fossella FV, Lee JS, Ki Hong W, et al. Management strategies for recurrent non small cell lung cancer. Semin Oncl 1997; 24: 455-62.